<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470326</url>
  </required_header>
  <id_info>
    <org_study_id>B1781007</org_study_id>
    <nct_id>NCT01470326</nct_id>
  </id_info>
  <brief_title>Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
  <acronym>VIOLINE</acronym>
  <official_title>ViviantÂ®20mg Special Investigation (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this survey, to collect the safety and efficacy information of Bazedoxifene in daily
      medical practice will be examined. In addition, the necessity of special Investigation and
      post-marketing clinical studies will be examined, while investigating unexpected adverse drug
      reactions during the survey period and understanding of the status of frequency of adverse
      drug reactions in daily medical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the subjects whom an investigator prescribes the first Bazedoxifene (Viviant) Tablets
      should be registered consecutively until the number of subjects reaches target number in
      order to extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of treatment related adverse events.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of all fracture.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related unlisted adverse events in Japanese Package Insert.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors likely to affect the frequency of treatment related adverse events.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3185</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Bazedoxifene Tablets</arm_group_label>
    <description>Subjects taking Bazedoxifene Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene</intervention_name>
    <description>For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.</description>
    <arm_group_label>Bazedoxifene Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects whom an investigator involving B1781007 prescribes the Bazedoxifene Tablets.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post menopausal women subjects with Osteoporosis who has no experience of use of
             Bazedoxifene.

        Exclusion Criteria:

          -  Subject with present or past venous thromboembolism such as deep venous thrombosis,
             pulmonary embolism, or retinal venous thrombosis

          -  Subject in long-term immovability (postoperative recovery, long-term bed rest)

          -  Subject with antiphospholipid antibody syndrome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1781007&amp;StudyName=Viviant%2020mg%20Special%20Investigation%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Post menopausal women</keyword>
  <keyword>SERM</keyword>
  <keyword>Japanese</keyword>
  <keyword>Viviant</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan</keyword>
  <keyword>Long term treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bazedoxifene</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 8, 2017</submitted>
    <returned>February 16, 2018</returned>
    <submitted>March 13, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

